EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale

Zhen Fan, Graham Searle, Gaia Rizzo, Justin Albani, Patrick Cella iD, Robert Comley, Gregory Klein, Luca Passamonti, Cristian Salinas, Adam J Schwarz iD, Leonardo Iaccarino, Gilles Tamagnan und 5 weitere

Annals of Neurology · 2026

DOI: 10.1002/ana.78116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2026. Verfasst von Zhen Fan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Xing Imaging-A Mitro Company, London, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Dopaminergic Neurons. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J. Fox Foundation, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Dopaminergic imaging is a key biomarker for both the investigation of the biology of Parkinson's disease and related synucleinopathies and the evaluation of potential therapies in clinical trials. This work presents a harmonized approach for quantifying dopaminergic molecular imaging tracers, such as [ 123 I]ioflupane (dopamine transporter scan [DaTscan]) single photon emission computed tomography (SPECT) and [ 18 F]AV133 positron emission tomography (PET), which assess dopaminergic neuronal loss. The proposed method aims to standardize regional outcome measures using a unified scale called Centamines.

Methods

The Centamines framework comprises 3 analysis levels. Level 1 defines the Centamine scale based on healthy subject data from [ 123 I]ioflupane SPECT (n = 224). Level 2 uses head‐to‐head data between Tracer X and [ 123 I]ioflupane SPECT to map Tracer X onto the Centamine scale. Level 3 maps additional tracers using prior mappings. A level 2 analysis was performed using [ 123 I]ioflupane SPECT and [ 18 F]AV133 PET data (n = 68) to convert [ 18 F]AV133 PET into Centamines.

Results

Level 1 successfully established the Centamine scale using healthy [ 123 I]ioflupane SPECT scans. Level 2 revealed moderate‐strong linear correlations ( R 2 = 0.51–0.83) between [ 123 I]ioflupane SPECT and [ 18 F]AV133 PET across 5 brain regions. Mapped Centamine values showed minimal differences between tracers, ranging from 1.5% (post‐commissural putamen) to 3% (caudate).

Interpretation

The Centamine scale holds promise for the harmonized quantification of dopaminergic neuronal imaging markers. The Centamine strategy would enable and accelerate clinical trials in Parkinson's disease using dopaminergic imaging outcomes. ANN NEUROL 2026;99:949–963

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDopaminergic NeuronsHumansTomography, Emission-Computed, Single-PhotonDopaminergic ImagingBiomarkersPositron-Emission TomographyMaleNortropanesFemaleAgedDopamine Plasma Membrane Transport ProteinsMiddle Aged

Substanzen

BiomarkersioflupaneNortropanesDopamine Plasma Membrane Transport Proteins

Autor:innen und Institutionen

  • Xing Imaging-A Mitro Company, London, UK.
  • GE HealthCare, Arlington Heights, Illinois, USA.
  • AbbVie, Chicago, Illinois, USA.
  • F. Hoffmann-La Roche, Basel, Switzerland.
  • Lantheus Medical Imaging, Billerica, Massachusetts, USA.
  • Takeda Pharmaceuticals International, Cambridge, Massachusetts, USA.

ORCID-Profile: Patrick Cella, Adam J Schwarz, Roger N Gunn

Förderung

  • Michael J. Fox Foundation
  • Denali, Edmond J. Safra Foundation
  • Eli Lilly, Gain Therapeutics
  • GE HealthCare
  • Genentech, GSK
  • Golub Capital, Handl Therapeutics
  • Insitro, Jazz Pharmaceuticals
  • Johnson and Johnson Innovative Medicine

Zitieren

APA

Fan, Z., Searle, G., Rizzo, G., Albani, J., Cella, P., Comley, R., Klein, G., Passamonti, L., Salinas, C., Schwarz, A. J., Iaccarino, L., Tamagnan, G., Eberling, J., Marek, K., Seibyl, J., Gunn, R. N., & Parkinson's Progression Markers Initiative (2026). Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale. Annals of Neurology. https://doi.org/10.1002/ana.78116

Vancouver

Fan Z, Searle G, Rizzo G, Albani J, Cella P, Comley R, et al. Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale. Annals of Neurology. 2026. doi:10.1002/ana.78116

BibTeX
@article{Fan2026,
  author = {Fan, Zhen and Searle, Graham and Rizzo, Gaia and Albani, Justin and Cella, Patrick and Comley, Robert and Klein, Gregory and Passamonti, Luca and Salinas, Cristian and Schwarz, Adam J and Iaccarino, Leonardo and Tamagnan, Gilles and Eberling, Jamie and Marek, Ken and Seibyl, John and Gunn, Roger N and Parkinson's Progression Markers Initiative, Parkinson's Progression Markers Initiative},
  title = {Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale},
  journal = {Annals of Neurology},
  year = {2026},
  doi = {10.1002/ana.78116}
}
Kostenlos starten →